Multidisciplinary | Home

Malaysia
Search
Sign In

Multidisciplinary Search

Multidisciplinary

Multidisciplinary

Home News Diseases Conferences Special Reports Multimedia

Methotrexate not better than placebo at maintaining treatment response for ulcerative colitis

9 hours ago

Parenteral methotrexate is not better than placebo at maintaining a steroid-free response or preventing relapse in patients with mild-to-moderate ulcerative colitis (UC), a recent study has shown.

Consumption of dairy, veggies and fruits factors in pregnancy outcomes

13 hours ago

Poor intake levels of dairy, vegetables and fruits may be a hazard during pregnancy, increasing the risks of adverse outcomes including low birthweight, preterm delivery and stillbirth, a study has found.

High femoral neck BMD tied to elevated risk of radiographic knee, hip osteoarthritis

21 hours ago

Individuals with increased femoral neck body mineral density (BMD) are highly likely to develop subsequent radiographic osteoarthritis of the knee and hip but not of the hand, a study suggests.

Fewer highs and lows with close-loop insulin therapy in T1D

Elvira Manzano, 23 hours ago

Hybrid closed-loop insulin therapy in patients with suboptimally controlled type 1 diabetes (T1D) helps to keep their sugar levels within range, a 12-week multicentre, multinational trial has shown, supporting the utility of closed-loop technology in clinical practice.

Optimizing CV outcomes with evolocumab

Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

An interview with Dato’ Sri Dr Azhari Rosman: Managing CV risk associated with T2DM

02 Oct 2018

Type 2 diabetes mellitus (T2DM) is associated with substantial risks of cardiovascular disease (CVD) risk and overall mortality, despite the advances in treatment options.¹ Recently, MIMS Doctor spoke to Dato’ Sri Dr Azhari Rosman, a Senior Consultant Cardiologist at the National Heart Institute, to provide an update on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in managing CV risk associated with T2DM, and discuss the results of the recently published Comparative Effectiveness of Cardiovascular Outcomes (CVD-REAL) 2 study. Here are the highlights from the interview.

Influenza prophylaxis: Improving antimicrobial stewardship and removing vaccination barriers

01 Sep 2018

The “Stay healthy: You call the shots” meeting, hosted by Sanofi Pasteur, was held at Thistle Port Dickson. During the meeting, Dr Ho Bee Kiau, Dr Leong Chee Loon and Dr Salehuddin Samsudin shared their insights into the role of influenza vaccination in reducing antimicrobial resistance (AMR), complications in high-risk patient populations, and dispelling vaccination myths among patients.

Lessons from the TREAT trial: Ticagrelor is as safe as clopidogrel for STEMI patients treated with fibrinolysis

01 Sep 2018

Ischaemic heart disease was the principal cause of death in Malaysia in 2016, and ST-segment elevation myocardial infarction (STEMI) is noted as the deadliest clinical presentation of Acute Coronary Syndrome. At the National Heart Association of Malaysia’s 2018 Annual Scientific Meeting, Professor Dr Wan Azman Wan Ahmad shared his insights into the management of STEMI in Malaysia, highlighting the implications of the recent TREAT trial.

Dolutegravir: Towards an ideal antiretroviral therapy for the treatment of HIV infection

13 Aug 2018

At a lunch seminar hosted by GlaxoSmithKline (GSK) at the University of Malaya Medical Centre, Dr Annemiek de Ruiter spoke on the recent updates on dolutegravir (Tivicay, GSK) as an ideal antiretroviral (ARV) agent for the management of patients with human immunodeficiency virus (HIV) infection.

Fewer highs and lows with close-loop insulin therapy in T1D

Elvira Manzano, 21 Oct 2018

Lixisenatide may delay kidney disease progression in T2D patients with macroalbuminuria

Roshini Claire Anthony, 20 Oct 2018

The GLP-1* receptor agonist lixisenatide may slow the progression of micro- and macroalbuminuria in patients with type 2 diabetes (T2D) and acute coronary syndrome, based on an exploratory analysis of the ELIXA** trial presented at EASD 2018.

Dual benefits of twincretin in T2D: HbA1c reduction & weight loss

Elvira Manzano, 19 Oct 2018

Treatment with twincretin, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1 receptor agonist combined into a single drug (LY3298176), not only reduced blood glucose in patients with type 2 diabetes (T2D) – it came with an added benefit of weight loss, with no increase in hypoglycaemia in a phase IIb trial.

BIONYX trial demonstrates noninferiority of durable zotarolimus-eluting stent to bioresorbable sirolimus-eluting stent

Roshini Claire Anthony, 19 Oct 2018

Percutaneous coronary intervention (PCI) with a thin composite wire strut, durable polymer-coated stent demonstrated comparable results to that using an ultrathin cobalt-chromium strut, bioresorbable polymer-coated stent, according to results of the BIONYX* trial presented at the recent TCT symposium (TCT 2018).

Dose and calcifications predict overall survival in NSCLC patients receiving RT

Dr. Joseph Delano Fule Robles, 19 Oct 2018

Investigators from the University of Manchester, Manchester, UK recently demonstrated a significant interaction between volume of identified calcifications and their mean radiotherapy (RT) dose in predicting survival in patients with non-small-cell lung cancer (NSCLC).

CARMELINA reassuring for linagliptin CV safety in T2D

Pearl Toh, 18 Oct 2018

Treatment with the DPP-4* inhibitor linagliptin in addition to the standard of care has no impact on heart failure, cardiovascular (CV), or renal events compared with standard of care alone in patients with type 2 diabetes (T2D) who had a very high risk of CV events and/or kidney disease progression, according to the CARMELINA** postmarketing outcomes study, thus providing reassurance on the CV safety of at least one member of the drug class.

Plant-based diet associated with reduced insulin resistance, T2D risk

Roshini Claire Anthony, 18 Oct 2018

Individuals who opt for a plant-based diet over an animal-based one may reduce their risk of developing insulin resistance or incident type 2 diabetes (T2D), according to a study from the Netherlands.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!